CurveBeam AI Advances $6.5M Placement with Partial Funds Settled
CurveBeam AI has received $5.6 million of its $6.5 million placement, issuing shares for the settled tranche while awaiting the remaining offshore transfer. The company plans to complete the share issuance once the final funds arrive.
- Received $5.6 million of $6.5 million placement funds
- Issued 62.2 million shares for the settled tranche
- Awaiting $0.9 million offshore transfer to complete placement
- Second tranche of 10 million shares pending upon receipt
- Placement supports funding for AI-driven medical imaging growth
Placement Progress and Share Issuance
CurveBeam AI Limited (ASX – CVB), a specialist in AI-powered medical imaging technology, has provided an update on the settlement of its recent $6.5 million capital raising placement. As of early October 2025, the company has received $5.6 million of the total placement proceeds and has issued 62.2 million fully paid ordinary shares corresponding to this tranche.
The remaining $0.9 million, sent via an offshore transfer from an investor, has not yet cleared into CurveBeam AI’s bank account. The company has received confirmation from the investor that the funds have been dispatched and expects receipt by the end of the week. Upon arrival, CurveBeam AI will issue a further 10 million shares to complete the placement.
Strategic Implications for CurveBeam AI
This capital injection is a critical step for CurveBeam AI as it continues to develop and commercialize its flagship HiRise™ CT scanner and AI SaaS clinical assessment solutions. These technologies target musculoskeletal conditions with advanced weight-bearing CT imaging, offering advantages over traditional CT and MRI scans.
Securing the majority of the placement funds and progressing share issuance signals investor confidence in CurveBeam AI’s growth trajectory. The company’s dual presence in Melbourne and Pennsylvania supports its global operations and innovation pipeline, positioning it well in the competitive medical imaging sector.
Looking Ahead
While the delay in receiving the final tranche introduces some short-term uncertainty, the company’s transparent communication and investor assurances mitigate immediate concerns. The completion of this placement will enhance CurveBeam AI’s balance sheet, providing further runway to scale its AI-driven imaging solutions and expand market reach.
Investors and analysts will be watching closely for confirmation of the final funds and subsequent share issuance, which will mark the full execution of this capital raising round.
Bottom Line?
CurveBeam AI’s near-complete placement settlement strengthens its capital base, but the pending offshore transfer remains a key watchpoint.
Questions in the middle?
- When exactly will the remaining $0.9 million offshore transfer clear?
- How will CurveBeam AI deploy the new capital to accelerate growth?
- Could delays in settlement impact investor sentiment or share price?
